Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

计划入组 18 人 · 首次发布于 2026 年 1 月 5 日

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

计划入组 12 人 · 首次发布于 2020 年 3 月 2 日

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

计划入组 36 人 · 首次发布于 2022 年 5 月 19 日

Lutetium-177 zadavotide guraxetan

Lutetium-177-PSMA-I&T

Lutetium Lu-177(Lutathera, Lumark, EndolucinBeta, Lutetium (177Lu) chloride Billev (previously Illuzyce))

Lu

T-Knife GmbH

Germany

PH & T SpA

Italy

T-Balance Therapeutics GmbH

Germany

ESMO and ASTRO 2024: Advances in Prostate and Bladder Cancer Treatment

ESMO 2024: Key Prostate Cancer Advances Highlighted

177Lu-PSMA-I&T Demonstrates rPFS Benefit in mCRPC Patients in ECLIPSE Trial